

**ADMINISTRATIVE PROCEEDING**  
**BEFORE THE**  
**SECURITIES COMMISSIONER OF SOUTH CAROLINA**

**IN THE MATTER OF:** ) **CONSENT ORDER**  
Lucy Duncan-Scheman )  
a/k/a Lucy Duncan )  
and ) **File No. 06007**  
Carolina Linkages, Inc. )  
d/b/a Carolinks, )  
\_\_\_\_\_  
**Respondents.** )

WHEREAS, the Securities Division of the Office of the Attorney General of the State of South Carolina (the “Division”), pursuant to authority granted in the South Carolina Uniform Securities Act of 2005, S.C. Code Ann. § 35-1-101 to 35-1-703 (Supp. 2006) (the “Act”), on or about April 20, 2006, received information regarding alleged activities of Lucy Duncan-Schemen (“Duncan-Scheman”) and Carolina Linkages, Inc., d/b/a Carolinks (“Carolinks”) which, if true, would constitute violations of the Act and/or South Carolina’s prior Uniform Securities Act, S.C. Code Ann. § 35-1-10 to 35-1-1590 (Supp. 2004) (the “Prior Act”);

WHEREAS, the information led the Division to open and conduct an investigation into the securities-related activities of Duncan-Scheman and Carolinks (collectively, the “Respondents”) pursuant to S.C. Code Ann. § 35-1-602;

WHEREAS, in connection with its investigation, the Division, on October 12, 2007, issued a Cease and Desist Order (the “Cease and Desist Order”) against Respondents;

<sup>10</sup> See, for example, the discussion of the "right to be forgotten" in the European Union's General Data Protection Regulation (GDPR), Article 17(1).

1. *What is the primary purpose of the study?* (e.g., to evaluate the effectiveness of a new treatment, to describe a phenomenon, to compare two groups, etc.)

1. *What is the primary purpose of the study?* (e.g., to evaluate the effectiveness of a new treatment, to describe a population, to compare two groups).

19. *Journal of the American Statistical Association*, 1933, 28, 273-285.

11. *What is the primary purpose of the following statement?*

1998-2000, and the first year of the new millennium. The last three years of the century were the most

For more information on the use of the *bioRxiv* preprint server, see the [bioRxiv](https://www.biorxiv.com) website.

19. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fig. 19)

19. *Leucosia* *leucostoma* (Fabricius) *leucostoma* (Fabricius) *leucostoma* (Fabricius)

10. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fig. 10)

For more information, contact the Office of the Vice President for Research and the Office of the Vice President for Student Affairs.

1. *What is the relationship between the two concepts of the state and the nation?*

10. *Leucosia* (Leucosia) *leucostoma* (Fabricius) (Fabricius, 1781: 100. Type locality: India).

WHEREAS, the Respondents have disputed and continue to dispute the allegations contained in the Cease and Desist Order and have not admitted any violations of the Act or the Prior Act; and

WHEREAS, Respondents admit the Securities Commissioner of the State of South Carolina (the "Securities Commissioner") has jurisdiction in this matter and desire to bring this matter to conclusion and have agreed, without any admission that there has been any violation of the Act or of the Prior Act, to the investor protections and remedies set forth below;

NOW, THEREFORE, it is ordered, and Respondents agree:

- a. Effectively immediately, Respondents and all persons under their direction or control involved in the offer or sale of the Carolinks shares will cease and desist from offering and selling unregistered securities in or from South Carolina and cease and desist from acting as unregistered agents in or from South Carolina;
- b. Effective immediately, any exemption available to the Respondents under the Act is revoked;
- c. Respondent Duncan-Scheman will not offer or sell any security in or from the State of South Carolina for a five-year period, which commenced May 1, 2007; and
- d. Respondents will pay an administrative fine in the amount of ninety thousand (\$90,000) dollars and investigative costs in the amount of ten thousand (\$10,000) dollars, with such fine and costs to be joint and several as to all executing parties.

Upon execution by the Securities Commissioner, this Order resolves Administrative Proceeding 06007 as it relates to the Respondents. This Order should not be interpreted to waive any (i) criminal cause of action, (ii) private cause of action that may have accrued to investors as

considered. The following table gives the results of the experiments on the effect of the different factors on the yield of the product.

Factor	Effect on Yield (%)
Temperature (°C)	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Time (hrs)	1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Concentration (M)	0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0
Pressure (atm)	1, 2, 3, 4, 5, 6, 7, 8, 9, 10
Constituent A	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent B	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent C	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent D	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent E	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent F	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent G	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent H	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent I	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent J	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent K	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent L	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent M	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent N	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent O	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent P	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent Q	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent R	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent S	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent T	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent U	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent V	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent W	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent X	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent Y	10, 20, 30, 40, 50, 60, 70, 80, 90, 100
Constituent Z	10, 20, 30, 40, 50, 60, 70, 80, 90, 100

a result of either of Respondents' participation in the security offerings described in the Cease and Desist Order, or (iii) other causes of action which may result from activities of the Respondents not detailed in the Cease and Desist Order.

So ORDERED this 18<sup>th</sup> day of February, 2008.

By:

  
Henry McMaster  
Securities Commissioner

Securities Division of the Office of the Attorney General


By: Tracy A. Meyers

Tracy A. Meyers  
Assistant Attorney General  
Securities Division

Date: January 30, 2008

WE CONSENT:

Respondent Lucy Duncan-Scheman


By: 

Lucy Duncan-Scheman

Date:

January 30, 2008

Respondent Carolina Linkages, Inc. d/b/a Carolinks

By: 

(name/position)

President, CEO

Date:

January 30, 2008

1. The first step in the process of creating a new product is to identify a market need or opportunity.

2. Once a market need is identified, the next step is to conduct market research to understand the target market and competition.

3. The third step is to develop a product concept and prototype.

4. The fourth step is to develop a business plan and financial projections.

5. The fifth step is to seek funding and partners to support the development and launch of the product.

6. The sixth step is to develop a marketing plan and strategy to promote the product to the target market.

7. The seventh step is to launch the product and monitor its performance in the market.

8. The eighth step is to evaluate the product's performance and make improvements as needed.

9. The ninth step is to continue to monitor the market and develop new products or features as needed.

10. The tenth step is to maintain the product and ensure its continued success in the market.

11. The eleventh step is to evaluate the product's performance and make improvements as needed.

12. The twelfth step is to continue to monitor the market and develop new products or features as needed.

13. The thirteenth step is to maintain the product and ensure its continued success in the market.

14. The fourteenth step is to evaluate the product's performance and make improvements as needed.

15. The fifteenth step is to continue to monitor the market and develop new products or features as needed.

16. The sixteenth step is to maintain the product and ensure its continued success in the market.

17. The seventeenth step is to evaluate the product's performance and make improvements as needed.

18. The eighteenth step is to continue to monitor the market and develop new products or features as needed.

19. The nineteenth step is to maintain the product and ensure its continued success in the market.

20. The twentieth step is to evaluate the product's performance and make improvements as needed.

21. The twenty-first step is to continue to monitor the market and develop new products or features as needed.

22. The twenty-second step is to maintain the product and ensure its continued success in the market.

23. The twenty-third step is to evaluate the product's performance and make improvements as needed.

24. The twenty-fourth step is to continue to monitor the market and develop new products or features as needed.

25. The twenty-fifth step is to maintain the product and ensure its continued success in the market.

26. The twenty-sixth step is to evaluate the product's performance and make improvements as needed.

27. The twenty-seventh step is to continue to monitor the market and develop new products or features as needed.

28. The twenty-eighth step is to maintain the product and ensure its continued success in the market.

29. The twenty-ninth step is to evaluate the product's performance and make improvements as needed.

30. The thirtieth step is to continue to monitor the market and develop new products or features as needed.

31. The thirty-first step is to maintain the product and ensure its continued success in the market.

32. The thirty-second step is to evaluate the product's performance and make improvements as needed.

33. The thirty-third step is to continue to monitor the market and develop new products or features as needed.

34. The thirty-fourth step is to maintain the product and ensure its continued success in the market.

35. The thirty-fifth step is to evaluate the product's performance and make improvements as needed.

36. The thirty-sixth step is to continue to monitor the market and develop new products or features as needed.

37. The thirty-seventh step is to maintain the product and ensure its continued success in the market.